| BIOPHARMACEUTICAL-CUSTOMERS |
BIOPHARMACEUTICAL-CUSTOMERS |
90%
|
Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research, clinical trial and real-world research related services. |
| LIFE-SCIENCE-CLIENTS |
LIFE-SCIENCE-CLIENTS |
90%
|
Commercial Solutions provides mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the … |
| FTRE |
Fortrea Holdings Inc. |
72%
|
$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be… |
| FTRE |
Fortrea Holdings Inc. |
72%
|
Reciprocal relationship from FTRE graph: Reciprocal relationship from IQV graph: $ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.5… |
| MEDP |
Medpace Holdings, Inc. |
72%
|
Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiven… |
| SPGI |
S&P Global Inc. |
72%
|
Reciprocal relationship from SPGI graph: Reciprocal relationship from IQV graph: $ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.5… |
| SPGI |
S&P Global Inc. |
72%
|
$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be… |
| TEM |
Tempus AI, Inc. |
72%
|
Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to t… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from IQV graph: ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology compan… |
| CHARLES-RIVER-LABORATORIES-INC-FORTREA-HOLDINGS- |
CHARLES-RIVER-LABORATORIES-INC-FORTREA-HOLDINGS- |
62%
|
$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be… |
| CMIC-HOLDINGS-CO-LTD |
CMIC-HOLDINGS-CO-LTD |
62%
|
ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to… |
| COGNIZANT-TECHNOLOGY-SOLUTIONS-DELOITTE-PHARMACE |
COGNIZANT-TECHNOLOGY-SOLUTIONS-DELOITTE-PHARMACE |
62%
|
ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to… |
| INFORMATION-TECHNOLOGIES |
INFORMATION-TECHNOLOGIES |
62%
|
ssments and other methods and resources to identify and manage cybersecurity risks. Our Integrated Information Security Framework ("IISF") defines minimum controls and safeguards used to safeguard pr… |
| INIZIO-SYNEOS-HEALTH-EPS-CORPORATION |
INIZIO-SYNEOS-HEALTH-EPS-CORPORATION |
62%
|
ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to… |
| MEDPACE-HOLDINGS-INC-S-P-GLOBAL-INC-DANAHER-CORP |
MEDPACE-HOLDINGS-INC-S-P-GLOBAL-INC-DANAHER-CORP |
62%
|
$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be… |
| PAREXEL-INTERNATIONAL-CORPORATION-PHARMACEUTICAL |
PAREXEL-INTERNATIONAL-CORPORATION-PHARMACEUTICAL |
62%
|
ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to… |
| PEER-GROUP |
PEER-GROUP |
62%
|
$ 2,163 November 1, 2024 – November 30, 2024 4.9 $ 206.15 4.9 $ 1,163 December 1, 2024 – December 31, 2024 0.7 $ 195.56 0.7 $ 1,013 5.6 5.6 Stock Performance Graph This performance graph shall not be… |
